%3Aformat(webp)&w=3840&q=75)
Gabather
Gabather targets mental health disorders by developing a specific GABAA receptor modulator in the central nervous system. The company is taking a new approach to a therapeutic area with a significant unmet medical need. The lead drug candidate, GT-002, is a potential first-in-class drug with solid clinical data from phase I studies. GT-002 is currently undergoing an exploratory phase II study in schizophrenia, the TOTEMS study, financed by Innovation Fund Denmark. The company is listed on Nasdaq First North since 2018 (ticker: GABA).
Stock price
Company information
No Data Available
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
